Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Novartis announced positive topline results from the Phase III PSMAddition trial for Pluvicto in metastatic hormone-sensitive prostate cancer (mHSPC), meeting its primary endpoint of statistically significant and clinically meaningful radiographic progression-free survival (rPFS) and showing a positive trend in overall survival (OS). These results suggest Pluvicto, already approved for metastatic castration-resistant prostate cancer (mCRPC), could be used in an earlier disease setting, addressing an unmet need; Novartis plans to submit for regulatory review in the second half of the year based on FDA feedback.

Analysis

Novartis (NVS) has announced highly positive topline results from the pre-specified interim analysis of its Phase III PSMAddition trial, where Pluvicto™ in combination with standard of care (SoC) met its primary endpoint for treating metastatic hormone-sensitive prostate cancer (mHSPC). The trial demonstrated a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS), alongside a positive trend in overall survival (OS), when compared to SoC alone. This outcome is significant as Pluvicto, a radioligand therapy (RLT), is already approved for later-stage metastatic castration-resistant prostate cancer (mCRPC), and these new findings suggest its potential to address unmet needs in an earlier disease setting, potentially delaying progression to mCRPC. This represents the third positive Phase III trial readout for Pluvicto, reinforcing its clinical value and Novartis's leadership in PSMA-targeted RLTs. The company plans to present full results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year. Novartis's broader strategy includes investigating a diverse portfolio of RLTs for other cancers and significantly investing in expanding its global RLT manufacturing infrastructure, including new facilities in Indianapolis and Carlsbad, to support growing demand and accelerate patient access.

Key Decisions for Investors

• Consider the positive PSMAddition trial results as a key value driver for Novartis, potentially expanding Pluvicto's market access into earlier-stage prostate cancer treatment and bolstering future revenue.
• Monitor upcoming catalysts for NVS, specifically the detailed data presentation from the PSMAddition trial and the subsequent regulatory submission and FDA feedback in the second half of the year, which could further influence the stock's performance.
• Evaluate Novartis's ongoing investments in its radioligand therapy pipeline and manufacturing capabilities as indicators of sustained growth and market leadership in this innovative oncology sector.